Anika Therapeutics Inc.
ANIK evidence brief
What we can confirm
- BioSniper Score:
- 7.8 / 10
- Market Cap:
- $275.5M
- Lead Asset:
- cingal (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ANIK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANIK
Anika Therapeutics is a hyaluronic acid (HA)-focused company that designs, manufactures, and commercializes osteoarthritis pain management and orthopedic regenerative solutions, with a portfolio centered on HA-based products and a recently completed strategic realignment.
Key risk: Regulatory approval risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$275.5M
Cash Runway
—
Lead Asset
cingal (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for Anika Therapeutics Inc..
Anika Therapeutics is a hyaluronic acid (HA)-focused company that designs, manufactures, and commercializes osteoarthritis pain management and orthopedic regenerative solutions, with a portfolio centered on HA-based products and a recently completed strategic realignment.
- Generated total revenue of $112.8 million in 2025, reflecting continued demand for its OA Pain Management portfolio and Commercial Channel growth [sec · filed 2026-04-28].
- As of 2026-06-30, the company reported cash & equivalents of $38.4M, total revenue of $32.6M, net income of $3.3M, and shareholders' equity of $137.3M [sec].
- Completed the divestiture of its Arthrosurface business in Q4 2024 and its Parcus Medical business in Q1 2025 to concentrate on HA-based programs [sec · filed 2025-04-28].
- Filed the final PMA module for Hyalofast in 2025 and received FDA feedback in early 2026, progressing toward a potential U.S. launch [sec · filed 2026-04-28].
- The Integrity Implant System achieved 40%+ sequential growth for three consecutive quarters after its launch [sec · filed 2025-04-28].
What works
- The company has a strong cash position with no debt, reporting $38.4M in cash & equivalents as of 2026-06-30 and a history of positive cash flow generation [sec · filed 2024-06-11] [sec].
- Its Commercial Channel, including the Integrity Implant System and international OA Pain Management business, has shown strong growth, with 16% year-over-year growth in international OA Pain Management in 2024 [sec · filed 2025-04-28].
- The company has advanced its pipeline, including filing the final PMA module for Hyalofast and receiving FDA feedback, positioning it for a future U.S. launch [sec · filed 2026-04-28].
What to weigh
- OEM Channel revenue declined due to anticipated U.S. pricing pressures, which may impact a historically cash-generative part of the business [sec · filed 2026-04-28].
- The company is dependent on regulatory approvals for key pipeline products like Hyalofast and Cingal, with no guaranteed U.S. launch timeline [sec · filed 2026-04-28] [sec · filed 2025-04-28].
- Recent executive leadership changes, including the transition of Dr. Blanchard to Executive Chair and Mr. Griffin to CEO in February 2026, introduce a period of management transition [sec · filed 2026-04-28].
From the filings
Quoted directly from source documents.
The company completed a strategic realignment by divesting non-core businesses.
“divested our Arthrosurface business in Q4 2024, and our Parcus Medical business in Q1 2025.”
SEC filings · April 28, 2025
Anika filed the final PMA module for Hyalofast and received FDA feedback.
“we filed the final PMA module for Hyalofast in 2025 and, in early 2026, received FDA feedback and are preparing responses”
SEC filings · April 28, 2026
The company has a healthy balance sheet with no debt.
“healthy balance sheet, positive cash flow generation and no debt.”
SEC filings · June 11, 2024
OEM revenue declined due to U.S. pricing pressures.
“OEM revenue declined due to anticipated U.S. pricin”
SEC filings · April 28, 2026
Risks & what to watch (3)›
Key risks
- Regulatory approval risk — U.S. launch of Hyalofast and Cingal depends on FDA approval, which is not guaranteed and may face delays [sec · filed 2026-04-28].
- OEM revenue decline — OEM Channel revenue declined due to U.S. pricing pressures, potentially reducing a key cash flow source [sec · filed 2026-04-28].
- Leadership transition — CEO transition in February 2026 may create short-term uncertainty in strategic execution [sec · filed 2026-04-28].
What to watch
- FDA feedback and next steps for Hyalofast PMA submission, as responses are being prepared [sec · filed 2026-04-28].
- Commercial performance of the Integrity Implant System and international OA Pain Management business, which have shown strong growth [sec · filed 2025-04-28].
- Impact of U.S. pricing pressures on OEM Channel revenue and overall cash flow [sec · filed 2026-04-28].
- Execution under new CEO Stephen Griffin, who assumed the role in February 2026 [sec · filed 2026-04-28].
Sources: SEC filings · Generated September 28, 2026 · How we verify sources →
Run Anika Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Anika Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.34 · 3% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
4 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 5.5%
- Days to cover
- 4.2
- Shares short
- 552,247
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANIK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Anika Therapeutics Inc.?
Anika Therapeutics is a hyaluronic acid (HA)-focused company that designs, manufactures, and commercializes osteoarthritis pain management and orthopedic regenerative solutions, with a portfolio centered on HA-based products and a recently completed strategic realignment.
What is Anika Therapeutics Inc.'s lead drug candidate?
Anika Therapeutics Inc.'s most advanced tracked candidate is cingal (Phase 3) for OA Pain Management.
Who is the CEO of Anika Therapeutics Inc.?
Mr. Stephen D. Griffin is the chief executive officer of Anika Therapeutics Inc. (ANIK).
Where is Anika Therapeutics Inc. headquartered?
Anika Therapeutics Inc. (ANIK) is headquartered in Bedford, MA, United States.
What therapeutic areas does Anika Therapeutics Inc. focus on?
Anika Therapeutics Inc. develops therapies across Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.